Cardiac disease in renal transplant recipients by Rigatto, Claudio




INFORMATlON TO USERS
This manuscriPt Ma been rep1:lduced from .... microIIm master. UMI fIms
.. text dNdIy from lie original or copy SfJbmitIed. nv... some thesis -.'Id
diI:seftMion copies .. ~ face. whie oIMws may be from My type of
""""*"_.
,.". ........."'---..--................. "' ....
copy aubmiIted. Broken or indistinct print, coIofed or poor quality illustrationslIfld_....._.__.lIfld _
_....-....-_.
In the ........,. 8'te1t lhlllihe -..char did not send UMI a awnpIeIe manusoipI
and ..... miMing p.tglIS. Ihese wiI be nded. -"10. if unauIhorized
copyright n'IIeiaI Met to be removed. a note wi. indicate the deletion.
"-- ..-.... (e.g.. "-. -.gs. .......) .. __ by
_ ...Of9neI._ .....__ """""lIfld""'*"*'ll
tn::mlefttDrightW'lequlllsec::tiof-.wiI'lsmeiovedlps..
~-""'0f9neI _
ll8ftIgf8phica1y in this copy. Higher queIity 6- l( g" black M\d white
~printI.. 8Y8iIatlIetorenyphotoliJl'aphsorilluatrationl~
in thiI copy for an Iddition8I dwge. Cantac:t 1.M diredty to order.
PYoQuest tnIonnation and lNrrWIg
300 NorI'l Zeeb Ro8d. Ann AftM)r. ,. 48106-1346 USA
800-521.Q600
UMf

.+.
=::=,-=-
---e:--QH .UAQNiI
.....
:=--
AcquiIiIicJrwet
.....~
---=ONK1AGJM
The _ has granted a DllIl-
exdusi>e Iiccoce aIIo..... dIeN_UInry ofCaoada to
--'1olo, _ ac sell
copies of Ibis 1hesis in microfurm,
paper or electronic formats.
The _mains owoenIUp ofdle
copyright in Ibis dlesis. Nei1her the
1hesis 00< subslantial_ from it
may be printed ac oIberwise
~ witbout the auIbor's
permissioo.
L•auteur a accord6 unc Ii<:ence non
exdusi>e pcnncItoDlila
BibIiolbOque _ du Caoada de
--.Jrite<, cIislrihae< ...
...... des copies de celie tbCsc sous
Ia forme de microfichclfilm, de
reprocIuctioo sur papier au sur format
&cttooique.
L '....... c:onser>e Ia propritte du
droit d'auteur qui protege celie tbCsc.
Ni Ia _ oi des exttaits-.;cls
de cdJe.ci DC _ CtR imprim<s
ou auttaDent rcproduits SIllS son
autorisation.
0-612-66794-4\
TIMsls Tide: c.+I.bi'f'C. l>tS~It"S£,~ ~c.. ~Sf\fH""
~tfuP"!N'n
This i5 to IUlborize the Dean o(CiI"IduMe SIUdic:s to deposit ""'0 copies of my thcsisiltpOn described above
in the Uuiveniry Libmy, on Ihr foLlowinS condilions. I unOmtllld thai I may choose ONE o(the options
here lisled, Ind may not ilJ'lcrwvdl IPflly (or allY addiriOQl.I renrietioa. I furtha- Widentand that the
Ulliveniry will nOllJllllll;llly restriction 10 !be publieation oflbesislrepon abstnctl.
(Aft~r rrodi"g f~UP/afUlftHJIltOlu'.1. d~/~k two af(a). (b) aM (e). ","idI~rQrr ,'"applk:abkJ
The c:onditionsofdeposit ate:
(I) lhlIllWOc:opicsatelOlxnllde.vaillblelOl&SeB.ltbedi5emiooortheitCU$!Od1ltlS,
~ tlu.lkttSSCSlO,mdqllOCltioollom.tIliI~reponislObeJl1lDledooJywithmywrillCn
pmnis.sioIl fOl'.periodofllDe)Ul'fromtbedaleOllwhic:h thetbe:sislrqlon..ll\er the approval of
the.ward ol!be depee. is CIltnasecd 10 !be CIR o(the UIlivftsity,llIlllCly. (gi~ dly. mexlIh. yeu)
..---'.ib'"'b"-I''''-~-_-.--',..,...."d"""""'......".-Of'"'...,--•.,.-=C=Otod~~ ...bichtimr; !be lWOeoplCS ate 10 be mack
Y WI accesses 10, and quowiOll (rom, this tbesislrepon: is 10 be granled only with my wrinen
pennission for.periodn( )'CltSfromtbedilcoo ....hiebthetbc:sislreport, i1ftef!be
i1Pf1fOvlloftheilwanio(thedegJe:e, is e'OlrUSled 10 tbe eareo(tbc Univcrsity, l\lIJ11ely, (give day,
monlh,ycar) ·after'tVbic:btimr;tbelWOeopicslrelObemadc
IVilililble 10 usen i111he disc:re1iOll ofrbeit custodilns.
NOT£S
I ~nttICJio« (b)..,;j/ iN l"'IJ'Iktlooo tIpfJIic«w... .....,....., t'ftlI<HI FWfI. Ho-wr.IIpp1~(itMs""I'U,"Cl_
(C} ...... iN~iftiwid.tkt(li/~upl,J_ioII.iJwIiaJMtwllJ'dwfll:Ul"ic:r.... islb""rol>ot
,,~._jQt~dw~ofIUW~~UIriaio#Is~... '_rr-USIIltJlIJw
tJwsUmponi:l~"""'""ppWJiuI..... or Npalall,,"_ilai. will_N~roU£Hd
"r«~ ~(Qcu"'~<MI]'h]'.c.....u-~bydwU.'-s./)'....lIl_(<U!:
ofUJ""i"illtSllld""'ic:IIio«s.."'/wiII"'~OIII,;.,~auu
~~......--uJctI""'.ifllw]'lut..""~;"t:OMfUOVQll'UHrd.d>q~·"""'
P/-.Jy~rofll:Ul"ic:rCfUlIOIItnr~po<fllifJj/I"_o{"""",lracI"' .... lwHfiJfill«J
StudUI N...t: 'c..+1Ioio C,".""7c) £••i1:e.lI(,ootT1"OCl ~.,,~.t"t6-~"
Addrftll: SbOO'il JT; 8oA.l"4"Le" 1IiDU¥T"'f1.
1(0," T~ '9'lfI' wr" JwciA (,.a.N .11"
Sign.cun: o.te: I ·01. a
CARDIAC DISEASE IN RENAL TRANSPLANT RECIPIENTS
By
Claudio Rigano
A thesis submined 10 the
School ofGraduate Studies
in partial fulfillment of the requirements for the degree of
MastcrofClinicaJ Epidemiology
School ofGnduate Studies
FacultyofMcdicine
Memorial UnivcrsityofNewfoundland
March 2001
St. John's, Newfoundland
ABSTRACT
CARDIAC DISEASE IN RENAL TRANSPLANT RECIPIENTS
Cardiac disease (eVD) is a major cause of morbidity in renal tnnsplant recipients (RTR).
The relacive importance oftradittonal YS. transplant-related risk factors. however. remains
controversial. while the impact of LV disorders has not been well studied. We conducted
two cohort studies to examine the incidence. determinanlS., and outcomes of LV disorders
in RTR, and 10 compare the relative importance of traditional V$. transplant-related risk
factors. In Study One (sequential echocardiograms in a prospective cohort of RTR), LV
hypertrophy regressed over the first two post transplant years and thereafter remained
stable. Older age and hypertension predicted. failure 10 regress. In Study Two (a
retrolcetive cohort study of 473 RTR), congestive hean failure (CHF) was as common
and as adverse a morbid event as ischemic heart disease (nID). Age, diabetes, gender.
blood pressure and anemia were the dominant predictors of CHF, while age, diabetes,
gender, blood prusure and cholesterol were the dominant risk factors for 1HD. The
dctenninants of de novo IHD in RTR were similar to those in general population,
whereas the detenninants of LV disorden arc similar to those in chronic renal
insufficiency. Transplant associated variables. with the exception of anemia. were not
strongly associated with outcomes.
Key Words: Renal transplantation. left ventricular hypertrophy, cardiovascular disease.
anemia. cohort study.
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CHAPTER.
INTRODUCTION
In 1836. Richard Bright observed thai palients with advanced w-emia had high mortality
rales and LV enlargement at autopsy {I). In 1911, Clyde Shields, the first chronic
hemodialysis patient, died of a m)"OCUdial infarction at age 50 (2]. While these two
signal observations highlight the long and historical connection between uremia and
cardiac disease, il is remarkable that during the 134 intervening years, almosl no research
was conducted on cardiac dysfunction in rmal failure. In contrast.. the subsequent three:
decades have added considerably 10 our understanding of the delenninants of LV
dysfunction and ischemic heart disease, albeit moslly in dialysis patients. In particular,
the imponance of LV dysfunction and CHF as major arbiters of prognosis and the role of
uremia.specifK: facton. especially anemia. in the development of cardiac dysfunction in
dialysis, are now well established. It is only in the past decade, however. that
investigatolS have turned their attention to determinants of cardiac disease: in non-dialysis
renal populations.
Cardiovascular disease (eVO) is now recognized to be the major cause of death among
renal transplant recipients (RTR). Between 11 and ID-4 of deaths on transplant are due [0
ev causes P,4) , and the incidence ofCVO among RTR appears to be increased 3 to 4
fold over that observed in age-matched control populations [3]. This risk is potentially
attributable to three risk factor categories: I) Traditional cardiac risk faclolS (as identified
by the Framingham Study) such as age, gender, diabetes, hypertension. hyperlipidemia,
and smoking [5], many of which are adversely altered by renal transplantalion 2) Risk
factolS related to the transplant state and its complications such as immunosuppression,
cydosporine vascular toxicity, gnd\ rejection, and viral infections (e.g. cytomegalovirus),
3) Risk factors related 10 loss of graft function such as anemia, salt and water overload,
and hyperhomocysteincmia. Few studies have anemptc:d to assess the impact and relative
importance of these risk factors in !he development of UID using a cohort design and
multivariate techniques[J,4,6-9] . Linle is known about LV functional disorders in
RTR, and no SlUdy has explored !he oulcomes of or risk factors for congestive heart
failure (CHF) in RTR.
In order to address these shortcomings, we perfonncd two studies lhal comprise the major
components of the present thesis. The first component is an analysis of serially obtained
echocardiograms in ttansplanted patients derived from a previous cohort. The main goals
of this study were to describe the changes in LV mass oa:uning after the first post.
transplant year and to detennine risk factors predicting these changes.
The second component of this thesis is a retrolecrive cohort study ofall RTR transplanted
in Manitoba between 1969 and 1998. The primary goals of the study were to define.
using multivariate techniques. the outcomes and risk factors for de novo CHF in RTR,
and to explore the interrelationships between de novo CHF. de novo ischemic Mart
disease (IHD) and monality in this patient population. A secondary objective was to
assess the relative importance of the major risk factor categories mentioned above. and in
particular to address the impact of renal function per se on the development of cardiac
disease.
Finally, we explore the implications these studies have for two clllTtntly dominant
paradigms of cardiac disease in renal disease: the notion of an "accelerated"
atherosclerosis in uremia and the notion ofa "'toxic" uremic cardiomyopathy.
CHAPTER 2
REVIEW OF THE LITERATtJRE
2.1 ~.. ltnrtdisaM: (IRD)vs.1dt vn-triallir (LV)disonIen
Cardiac disease may be categorized into disorders of perfusion and disorders of cardiac
geometry and function. From a theoretical perspective. they each represent adaptive (or
maladaptive) responses of specific: organ systems to specific physiological Stressor'S, and
can be thought of under the general rubric of""response to injury". Disorders of perfusion
are primarily. but not exclusively, related to atherosclerotic disease of the coronary
arteries. and thus the story of ischemic heart disease is in great part the story of
atherogenesis and its determinants. Disorders of cardiac geometry (LVH, dilatation) and
function, on the other hand. are aspects of a global vascular adaptation to hemodynamic
stress. Although these disorders are closely interrelated, occur together frequently in the
same patient and share several risk factors in common. they are nevertheless distinct
pathophysiological entities.
2.2 LV disorden • RTR
Ventricular growth occurs in response to mechanical str~sses, primarily volume or
pressure overload [IOJ (Fig. 94-2). Volume overload results in addition of new
sarcomcres in series. kading to increased cavity diameter [II]. A larger diameter results
in increased wall tension, a direct consequence of Laplace's Law, which Stales that wall
tension (T) is proportional to the product of intraventricular pressure (P) times the
ventricular diameter (D): in symbols. T=PD/4. An increase in wall tension secondarily
stimulates the addition or new sarcomeres in parallel. This remodeling thickens the
ventricular wall, distnbuting the tension over a larger cross-sectional area or muscle and
returning the tension in each individual fiber back to normal, alleviating the stimulus to
further hypertrophy. This combination of cavity enlargement and wall thickening is
called eccentric hypertrophy. Pressure overload increases wall tension by increasing
intraventricular pressure, resulting directly in the parallel addition of new san::orneres and
its functional consequences as described. Since sarcomercs arc not added in series,
isolated pressure overload does not lead to cavity enlargement, although dilatation may
occ:ur late in the evolution of the hypertensive heart. Muscular hypertrophy without
cavity enlargement is called concc:nbic hypertrophy.
Both eccentric and concentric hypertrophy are initially beneficial. Dilalation pennilS an
increase in stroke volume without an increase in the inotropic state of the myocardium
and as such is an efficient adaptation to vohune overload [l2J. It also permits the
maintenance ofa nonnal stroke volume and cardiac output in the presence of decmued
contractility. Muscular hypertrophy returns the tension per muscle fiber back to nonnal,
decreasing ventricular stress.
Ultimately, LVH becomes maladaptive. Muscular hypertrophy is associated with several
progressive. deleterious changes in cell function and tissue architecture. Early in the
evolution of LVH. slowed re-uptake of calcium by the sarcoplasmic reticulum (SR) leads
to abnonnal ventricular relaxation. Combined with decreased passive compliance of a
thickened ventricular wall, these changes may precipitate diastolic dysfunction [13].
More advanced SR dysfunction is associated with calcium overload and cell death.
Decreased capillary density, impaired coronary reserve and abnonnal relaxation may
decrease subendocardial pcrl'usion, promoting ischemia [14). Frequent coexistence of
CAD may exacerbate ischemia and m)'OCyte attrition [IOJ. Fibrosis of the cardiac
interstitium also occun [IS], and appears 10 be more rrwtced in pressIft than volume
overload. Myocyte apoptosis, ischemia, neurohormonal activation (i.e. increased
catecholamines, angiotensin U, aldosterone, among others) is thought to contribute
[12,16,17]. In the late phases of chronic and sustained overload, oxidative stress is
prominent and contributes to cellular dysfunction and ~se (18]. Together, these
various processes lead 10 progressive cellular attrition, fibrosis, congestive heart failure
and, ultimately, death.
The renal transplant milicu may potentiatc many of these processes. Hypertension is
prevalent among RTR and is a major contributor 10 pressure overload [19-2IJ
Calcincurin inhibitors (Cyclosporine, FK.506), allograft failure. acute rejection may all
promote hypertension and thus LVH and CHF [19-22). In failing allografts, anemia and
sodium retention, may add flow (volume) overload to preexisting pressure overload.
Mycophenolic acid and azathioprine are marrow suppressive, and may exacerbate anemia
in the setting of progressive graft failure. Anemia promotes vascular remodeling, leading
10 muscular hypertrophy and dilatation of the left ventricle in chronic renal failure and
dialysis patients [23]. This association may pertain in RTR as well. The primary stimuli
for ventricular remodeling, pressure and flow, also promote concomitant arteriaJ
remodeling in the large and resistance arteries. This remodeling is characterized by
diffuse arterial wall thickening and stiffening (arteriosclerosis), which can increase the
effective pressure ~ on the left ventricle independently of mean arteriaJ pressure
[24,25].
The attrition of myocytcs in RTR may be exacerbated by several factors.
Underlying CAD promotes ischemia and infarction. n.e role of puwive risk factors for
1HD in RTR is discussed in the next section. Immunological phenomena such as acute
rejection episodes may contribute to oxidative stress, which may in tum promote cellular
dysfunction and apoptosis[18]. Progressive loss of renal function from chronic allograft
nephropathy may be lead to malnutrition and hyperpar.uhyroidism [10.26] . The former
may contribute to cell apoptosis and the latter to myocyte dysfunction and cardiac
fibrosis. Such cell death in the presence of LY hypertrophy and continuing pressure and
volume overload leads ullimately to the clinical manifestations ofcongestive heart failure
[27J.
2.2.2 EpId<"""'"
Disorders of LV geometry begin during chronic renal insufficiency, well before
transplantation and indeed well before dialysis. In a cross-sectional study conducted by
Greaves and coworkers, patients with chronic renal insufficiency (serum creatinine> 3.4
mgldl) had mean LV mass index of 120 g/m l , which was intennediate between that of
gender and age matched controls (79g/m1) and dialysis patients (136 g/m1)(28]. An
abnonnal echocardiogram, primarily LYH, was observed in 63% of chronic renal
insufficiency patients, versus 7r.4 of dialysis patients, suggesting a relationship between
LY morphology and worsening renal function. Levin et aI have reponed a prevalence of
LVH of 26.7% in patients with creatinine clearance >50 mUmin, 30.8% in those with
clearances of25-49 mUmin. and 45.2% in those with clearances <25 mllmin [29]. In the
prospective ann of this study. an association between rising LV mass index and falling
GFR was observed. Another cross-sectional study has yielded comparable results [301.
The overall prevalence ofLVH among patients beginning dialysis is 75% [31.34J . In a
large prospective cohort study, only 16% had normal echocardiograms at inception.
Fifteen percent (15%) had systolic dysfunction, 28% had dilatation with preserved
contractility, and 41% had concentric LVH [27]. In a subset of dialysis patients who
underwent yearly consecutive echocardiograms. LV mass index and LV cavity volume
progressively increased, the biggest increase occurring between baseline and year [35J.
By the time patients are transplanted. therefore, a significant proportion has
echocardiographic abnonnalities. In one longitudinal study. echocardiograms were
performed just prior to transplantation and then one year post transplantation. Qfthe pre-
transplant echocardiograms, 1,..4 exhibited nonnal geometry, 41% showed concentric
LVH. 32% LV dilatation, and 12% systolic dysfunction [36]. The proportion of patients
with nonnal studies doubled (36%) and systolic function nonnalized in all patients with
fractional shortening < 25% at one year post-transplantation [36). Several other studies
have confirmed improvement in LV function after renal transplantation. Neither the Iong-
term evolution of LV changes, nor the development of clinical CHF, has been studied to
date in RTR.
PotntiIIJ risA/con lor LVmtmIns
Age: Age is an established clinical marker of risk for LVH in the general. CRt and
ESRD and RTR populations [29,37-39J
Gender: The role of gender as a risk factor for LV disorders is less clear. In a registry
based study of dialysis patients, women were found to be more likely to have
radiographic cardiomegaJy or a history of CHF and less likely to exhibit
electrocardiographic or cchocMdiographic evidence of LVH tlwt men [40]. In contrast
to this result. a large prospective cohon study of patients beginning dialysis in Canada
found no relationship between gender and development of hean failure. Moreover.
femaIe gender was associated with concentric LVH. whereas male gender was predictive
of LV dilatation and congestive heart failure [4IJ. These contrasting findings may relate
to differences in sample size (SOOO in the fonner vs. 432 in the latter), design
(reU'OSpCCtive cohon n. prospective cohon). and criteria for LV geometry. The role of
age and gender in the evolution of LV disorders or CHF among RTR has not been
examined. However. given the possible importance of gender in disease states in general.
it must be considered as potential risk factor. ifonly for the purpose ofrisk adjustment.
Diabetes MeWlw: There is evidence for a specific diabetic cardiomyopathy in diabetic
patients without ESRD [42. 43J . LVH is a more frequent finding in hypertensive diabetic
patients than in hypertensive non.diabetic patients, as is cardiac fibrosis [43.44) .
Diabetes has been identified as a predictor of hypertrophy in dialysis patients {26,28]. It
is unknown whether diabetes is a risk factoT for LV disonten or CHF in RTR.
Hypertension: The role of h)'pencnsion in the evolution of LVH or CHF remains
controversial in all renal failure populations. Studies in dialysis patients have shown an
inverse relationship between blood pressure and monality. with hypertension predicting
longer survival [45.46] . However. the high prevalence of cardiac disease at the start of
ESRD therapy is a source of confounding even for well-exccuted prospective cohon
studies. Since cardiac dy5function can cause low blood pressure (so-called "reverse
causality") and is independently associated with death, even prospective studies cannot
exclude the possibility that low blood pressure is simply a SWTOgale marker for poor
10
pump function. unless patients with cardiac abnonnalities II baseline arc excluded from
analysis. This is difficult to do in practice, since the majority (75-80%) of patients have
cchocardiographic abnonnalitics at the start of maintenance dialysis. (n one prospective
cohort study of 433 dialysis patients, rugh blood pressure was positively associlled with
the development of lHD and LVH but negatively associated with mortality (48% rugher
risk of LV hypertrophy for each 10 mmHg increment in blood pressure) [47). In this
same cohort. LVH was predictive of CHF, wruch in tum was associated both with
mortality and with a drop in mean arterial pressure. Lower mean arterial pressuR
following an episode of CHF was independently associated with mortality. These
observations suggest, but do not prove, the following causal sequence:
Hypertension -+ IHO and LVH -+ Pump failure -t Hypotension and Death
In a large cohon of CRI patients., in whom pccvalcnce of preexisting LVH was
approximately 300/0, hypertension was an independent risk factor for LV growth [23]. To
date. no studies have examined the impact of hypertension on LV disorders or CHF in
RTR.
Anemia: Anemia has been associated with LV dilatation and LV hypcnrophy in chronic
renal insufficiency and in dialysis patients (RR for LVH progression, per 10 giL drop, is
1.74 in CRI and 1.48 in dialysis) [23.26,35,4&-50] . Anemia is also a risk: factor for the
development of de novo cardiac failure and death in dialysis [50]. Partial cotTeclion of
anemia is associated with regression of hypertrophy in cohon studies [51,52] . The
impact ofanemia on the heart of RTR has not to date been studied.
Ischemic Hean Diseau: The risk. factors and outcomes for 1HD are discussed in the next
section. Nevertheless, it is wonh mentioning that coronary ancry disease is an imponanl
\I
cause of systolic and diastolic dysfunction in the general population and in dialysis
patients [26, 531, and likely continue to influence LV geometry and function in RTR.
Renal Functiotl: Dcc:lining function of native kidneys has been associated with LV
growth in CRt patients [23]. Once patients are on dialysis, LV growth tends to accelerate.
Renal transplantation appears 10 favor nonnalization of systolic dysfunction and
regression of concentric LV hypertrophy and LV dilatation, atlcasl in individuals without
clinically evidenl nm {36]. Whether impaired allograft function independently affects
the evolution oflV disorders or the onset ofCHF is unknown.
Hypoalbuminemia: Stvcnl studies have shown that hypoalbuminemia is a pmiictor of
CV disease in dialysis and among RTR. Hypoalbuminemia tw been associated with LV
dilatation and predisposes to de novo cardiac failure and ischemic heart disease among
paticnLS starting dialysis [54]. The mechanisms underlying this association are unknown.
Hypoalbuminemia is associated with a hypcrcoagulable state and may therefore
predispose 10 myocardial infarction and ischemic cardiomyopathy. Alternalively, it may
be a mariccr for malnutrition, inadequate dialysis., vitamin dcflCiency, or a chronic
inflammatory state, all of which could hypothetically accelerate myocyte death and the
development of cardiomyopathy, as discussed earlier. The impact of hypoalbuminemia
on CHF and LV disorders among RTR is nol known.
The impact of LV disorders or CHF on morbidity and mortality has nOI been sludied in
RTR. In dialysis palients., both echocardiographic and clinical evidence of ventricular
dysfunction predict adverse prognosis. The presence of concentric LVH, l V dilatation
with nonna! contractility and systolic dysfunction at baseline has been associated with
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progressively worse survival (figure 94-4). independent ofage., gender, diabetes and nm
(32]. All three abnormalities are also associated with increased risk for the development
ofcongestive bean failure. In a Canadian cohort, the median survival of patients who had
heart failure at or before initiation of ESRD therapy was 36 months, compared with 62
months in subjccts without baseline CHF. The risk o( developing pulmonary edema
requiring hospitalization or ultrafiltration after starting maintenance hemodialysis was
10-;. annually (41,55]. CHF was found to be a suonger prmictor of death than lHD.
Based on the data above, we expect that CHF will be a prognostically significant morbid
event in RTR, although the frequency with which it occurs may be [ower than in dialysis.
2.3 IHD .. RTR
2.3.1 httoopilYlioIocY
In non·renal (ailure populations, the initiating event of atherosclerosis appears to be
endothelial injury caused by mechanical stress (e.g. hypertension) or endothelial toxins
(nicotine, oxidative stress, hyperlipidemia, inflammation). This stress alters endothelial
phenotype to a more penncable, activated stale (56]. Endothelial denudation or, more
commonly, alterations in endothelial cell surface reccptor expression, permit access o(
lipoproteins and macrophages into the subintimal space [56,57). Oxidative modification
of lipoproteins, particularly LOL (ox-LOL), is chemotactic for macrophages and
facilitates uptake of oxidized lipids by macrophage FC receptors, resulting in formation
of foam cells [58}. Ox-LOL stimulates elaboration of growth factors that are mitogenic
for smooth muscle and promote fibrosis [59). Tbcsc processes result in the accumulation
of oxidatively modified lipids and inflammatory cells at the center of a fibrous "cap" of
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variable thickness. This cap may rupture, causing thrombosis that may be minimally
symptomatic or associated with acute coronary syndromes (e.g. unstable angina,
myocardiallnfart:tton).
Several factors characteristic of the renal transplant state may modify the process of
atherogenesis. Many traditional risk factors such as hyperlipidemia. hypertension, and
diabetes are more prevalent or else are more severe in renal transplant patients [19-21].
These factors probably continue to innuence atherosclerosis and vascular remodeling in
RTR.. lmmtmOSUpJeSSive agents like cydosporine., prednisone. and tacrolimus may
exacerbate hypertension, hyperlipidemia. and diabetes [22,60-63J . Cyclosporine may
in addition promote oxidation of LDL and may directly activate endothelium and
platelets [64-66] . Acute rejections are associated with up-regulation of inflammatory
cytolOnes that may activate endothelium, thus directly influencing vascular disease, or
may have indirect effects mediated by hypertension or resultant chronic graft failure.
Chronic graft failure in turn may be associated with oxidative stress. chronic
innammation. anemia. and LVH, all of which may directly or indirectly influence
atherogenesis [18.23.67,68] .
2.3.1 EpideDliolosY
6.,.../iisaK
Among renal transplant recipients (RTR), the overall prevalence of CAD is
approximately 15% [3J .The annual incidence ofMI, revascularization. or death from MI
among RTR is 1.5% [6J. These estimates are similar to those reponed for chronic renal
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insufficiency (CRI) (1-3% per year incidcnc:e) [69.71),_ and lower than in dialysis
(IQ-/Jyear) [55). Cardiovascularcauscs account fori 7·SO-Ie of deaths among RTR (3,4)
Age: Advancing age is associated with an increased risk of IHD in the general population
[n,73). Older age has been independently associated with arteriographic CAD [74] ,de
novo occurrmce of angina pectoris. myocardial infarction, or col'OlW)' revascularization
in dialysis palients[4S) (relative risk (RR) 1.6 per decade), and increased risk of death
among dialysis patients (75). Among RTR, age appears to be an independent risk factor
for MI or coronary revascularization or death from Ml (RR 1.5 per decade)[6], and for
all cause death (RR 1.5 per decade)[76).
Diabetes Mellitus: Diabetes is independenUy associated with a relative risk of 1.5-2.2 for
the development ofCAD in the general population [77-81) . The link with nm events
in the CRI population has not been explicitly stUdied but is probably intermediate
between the general population and dialysis patients. Among dialysis patients, diabetes is
independently associated with the development of de novo IHD and death (adjusted RR
3.98 and 3.86, respectively) [45,76). Among RTR, diabetes is strongly associated with
multiple can:liovasculac outcomes (RR of 2.09 for Ml, revascularization, or death from
Ml; RR 2.98 for ischemic stroke, and RR of 25.7 for development of peripheral vascular
disease)[6].
Hypertension: Hypertension is a long established risk factor for IHO in the general
population [82,83]. PM.'ltIacological therapy of hypertension reduces the risk of MI by
14-16% for each 6 mmHg reduction in diastolic BP [84,85) .
"
1bc: role ofhypenension in lhe evolution ofIHD in renal patients remains eonuoversial.
Siudies in dialysis palienlS have shown an inverse relationship between blood pressure
and mOr1alily, likely as a resull of reverse causality as previously discussed. No sludies 10
date have assessed the role ofhypenension in the evolution oflHD in CRI.
1bc: prevalence of hypertension among transplant recipienlS is 70% 10 80% {6]. Elevated
blood pressure has been associaled with sbonened graft and patienl survival. as well as
higher rates of coronary artery disease (86.87) . However, retrospective analysis of large
transplant cohorts have not found an association between hypenension and monality after
adjustment for age, diabetes., tobacco use. and time on dialysis prior 10 transplantation
(6,88]. Further study is needed ofthe hypertensionlIHD link in RTR populations.
Smoki1/g: Smoking is a powerful risk factor for lHD in the general population,
approximately doubling the risk of CV events in the Framingham cohort [89]. Smoking
cessation can reduce the risk ofIHD by 50% even in longtime heavy smokers (90].
In dialysis, approximately 3()..4()% of palients starting dialysis are smokers {45.55]. and
smoking has been associated with an excess mortality of 26% in incident hemodialysis
patients, even after extensive covariate adjustment [87].
Among RTR, 25 to 4()-1. smoke at the time of transplant assessment. Most continue to
smoke after transplantation [20.91,92]. A smoking exposure of 10 10 25 pack-years has
been independently associated with ischemic stroke (RR 1.2 to 1.6). peripheral vascular
disease (RR 1.2-1.6). and mortality (RR 1.4-2.0) [6.92,93]. A specific association with
llID has not yet been documented.
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/Jy!/ipiJemia: Ebaled total cholesterol (TC). 10..... density lipoprotein (LDl-C),
lipoprotein(a) (Lp(a», tliglycerides (TG) and low high density lipoprotein (HOL-C) are
associated with IHO in the general population, and the efficacy of targeted LDt·C
lowering with HMG-CoA reductase inhibitors has been established in clinical trials [93-
98) . An atherogenic lipKJ profile is highly prevalent in patients with renal disease
(Table 94-1) {991. particularly in patients with nephrotic syndrome (NS).
With respect to clinical outcomes, there are yet no data linking hypercholesterolemia to
cardiovascular disease in CRJ.
Among dialysis patients, the data are conflicting. The highest mortality risk appear! to be
associated with low. not high cholesterol [100]. However, low TC is snongly com:lated
with poor nutritional status and low albwnin levels. both of which are associated with
increased monality risk. It is therefore unclear whether low TC is causally related to
death, or is a marker for malnutrition, hypoalbuminemia, or other yet unknown facton
associated with death. Although definitive data are lacking, it is biologically plausible
that high TC and LOL-C be risk factors in adequately nourished dialysis patients, as they
are in the general population.
In RTR. h)1)CfCholesterolemia (3.101) and low HOt [6] have both been linked to
ischemic events.
Other risk facron: Homocysteine is a nanually occurring byproduct of methionine
metabolism, a sulfhydryl-containing essential amino acid. Several large observational
studies have shown that elevation in plasma homocysteine is independently associated
with cardiovascular disease in the gcnera.I population [102-104] . limited prospective
data in RTR • CRI and dialysis suggest that Hcy may be an independent risk factor in
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these populations as well [lOS·IOS] . Chronic endothelial activation or injwy. activation
of prothrombotic factors. oxidative stress. and chronic inflammation may all contribute to
CV risk [18.109·113] . Viral infections. particularly CMV. have been associated with
nm in the general population and may be relevant to the renal tr'anSplant population as
well[II4-115].
CIu.ictl1 tHllCOMe
Registry and retrospective cohort data show that presence of nm in patients starting
dialysis is associated with excess short and long-term mortality (87,116]. In a Canadian
prospective cohort study, patients with clinical lHD at the start of dialysis were more
likely to have an admission for CHF (RR 1.7) or to die eRR 1.5) than patients free of nm
at baseline, after adjustment for age and diabetes (45]. In these patients. most of the
excess mortality associated with nm seemed. to be via the development of congestive
heart failure. In diabetic RTR. presence of lHD at baseline is associated with a fourfold
risk of future events and death (117). IHD is likely to exert a powerful influence on
survival in non-diabetic RTR as well.
2.4 Multlv.ri.le studies of C.rdJK dlHue I. RTR
The retrolcctive or prolective cohort studies involving more than 100 patients and
employing multivariate techniques in the analysis of cardiovascular risk factors are
summarized in Table 2.1 [4.6·9]. Outcomes and risk factors were measured or defined
differently. precluding a fonnal meta-analysis. Some studies have colTObonted the
importance of selected Framingham risk factors, othen the importance of transplant risk
factors. Importantly. no studies found blood pressure to be predictive of cardiovascular
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events on multivariate modeling. None of the studies examined the role of anemia in CV
disease. No study to date has examined the occurrence and impaci ofCHF in RTR. Few
studies have comprehensively examined all relevant potential risk factors simultaneously.
Since most risk factors are correlated to some degree with each other (e.g. age and rena1
function. hyperlension and cyclosporine use), simultaneous modeling of all putative risk
factors is crucial in assessing which risk factors dominate. Only one study has separately
examined de novo cardiac events occurring after the first post uansplant year Pl. Since
prevalent CV disease at baseline is predictive of recurrent CV disease and since early
events in !he first post transplant year may relate more 10 pre.transplant risk exposure.
analysis of events in the first year could obscure the effect oflransplant relaled variables.
An analysis of de novo cardiac events after I year. coupled with comprehensive risk
factor assessment and simultaneous, multivariate modeling of these risk faclon coukl
shed lighl on the relative importance of lransplant and traditional risk factors in the
development ofIHD in RTR.
2.S lalerrdatioe.sIIips bdweea risk fadon ill RTR
Figure 2.1 summarizes some of the possible causal relationships between risk factors and
cardiovascular outcomes in RTR. Most pathways are heavily inlertwined, making it
difficult to discern which pathway(s) dominate based on pathophysiological argumenlS
alone. We have suggested in this figure that alterations in traditional Framingham risk
factors are the moSI important but this is not clearly established. Epidemiological studies
might clarify this issue by detennining the strongest predictors of clinical events.
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Table 2.1: Cohort studies of cardiovascular risk in RTR
Study Multivariate Risk Factors
Kasiskc Age. OM. gender.
splenectomy, rejection,
lipids
eVA
1'00 10M, ,mok;og, ,ojc,";oo,PVO
'00 albumin
OM, smoking, gender.
albumin
Kasiske 17 I Re1rolective I Yes 11124 I Yes I Yes ItHO I Not Age. OM, rejection.
staled albumin. proteinuria.
Ii ids
Lindholm 14 IProlective IYes 11347 I Yes INot (HO Not Age, OM, gender,
applicable mortality stated rejec::tion, DGF. pre-
lransnlanl transfusion
Aker Ig I RClroleclive 1Yes 1427 INO IYes AlleV 4.9 OM, age, 8MI, SmOking,
events Ii ids urate
Ducloux 19 IProlective INo 1 207 1y~ 1 No AlleV g.g Hey. age, renal function,
events 2cnder
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CHAPTER)
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3.1 ._trod_diN
In pre-dialysis and dialysis patients. abnormalities of left ventricular geometry and
function arc conunon, progressive and closely associated with cardiac failure and death
[29,32,.35,1 18J. PartiaJ regression of LV hypertrophy (LYH) is known to occur in the
first year following lransplantation (36). The evolution of cardiac structural changes
beyond the first post-transplant year, however, is unknown. The objectives of the current
study were to describe the long-tenn evolution of 1.VH following renal transplantation
and to determine risk facton for its progression.
3.2 Met'ods
Patients: A prospective iocqMion cohon of 433 dialysis patients was assembled at three
Eastern Canadian centers from 1982 to 1991. The selection criteria and definitions used
for this cohort have been reported in detail elsewhere [32,118). One hwtdred and forty-
three (143) patients received renal allografts and comprise the study population. These
patients continued to be followed according to the study protocol until study termination,
death or loss to follow-up.
Data collection: Echocardiograms wcre scheduled at yearly intervals. Lcft ventricular
mass was calculated according to the Penn convention (119) while Icft ventricular cavity
volume index was calculated using the formula of Pombo ct al [120]. Systolic and
diastolic blood pressure, hemoglobin, serum creatinine, albumin, calcium, and phosphatc
wcre determined monthly. Serum total cholesterol was determined yearly.
Data analysu: Changes in LVMI and cavity volume index between echocardiograrns
performed at years 1,2,3 and 4 post.tnnsplantatton were compared using individual
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paired T-tc:sts., with Bonfmoni correction for multiple comparisons. To explore the
determinants ofchanges in LVMl between the first and second years, we used mulliple
linear regression to model the change in LVMl as a function of several predictor
variables (Table 3.1) in patients who had echocardiograms done in both years. LV
strUCtUre at year I was classified according to a previously defined classification system
(32,118). Hypertension was defined as blood preuure~erthan 140190 mmHg, as in
previous publications from this cohort [32,35,118J. Longstanding hypertension was
defined as blood pressure greater than 140190 mmHg for greater than 10 years.
McHenry's Sdection Algorithm was used to identify the subset of variables having the
strongest association with change in LVMI (Ness software, version 2(00).
J.J ReHlb
Baseline charaCleristics ofthe patients: Table 3.2 summarizes the baseline characteristics
of the transplanted individuals. Transplanted patients were young and had little
cardiovascular morbidity at the start of end-stage renal therapy. The median duration of
dialysis prior to transplanwion was II (7.21) months (median (25th, 75th percentile)] in
the transplant group. Median follow-up for the transplanted cohort was 38 (17,58)
months
&hocardiograms: Oflhe 143 transplanted patients, 113 had one interpretable post-
transplant echo, 70 had a second echo, 40 patients a third, and 18 a fourth. An echo was
deemed unintcrpretable if essential measurements were missing, preventing calculalion of
LVMI or LVCVI. A patient was deemed lost to follow-up ifhe or she survived for at
least one year after the previous echo without having a subsequent echo. Thirty-live
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patients (2.5%) were either lost to follow-up« had uninlerprdable ec:bocardiograms. The
remaining patients reached a censoring endpoint (death, graft failure, or study
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Table 3.1: Variables tested in the multiple
regression anaJysis of predictors or change
in l V mass index from year I to year 2 in
renal transplant patients.
V.JUbIe
Age at transplanwion
Diabetes
Smoking
Congestive hean failure at baseline
Ischemic heart disease at baseline
Duration of hypertension > 140190:
>10 yeaB
slO years
Blood pressure
Systolic
Diastolic
Pulse pressure
Number ofantihypertensives required:
<2
.2
Type ofantihypertensive:
ACE[
Beta blocker
Calciwn channel blocker
00«
Cyclosporine use
Hemoglobin
Creatinine
Albumin
Calcium
P!>o>ph.o,e
Cholesterol
Left ventricular morphology
Eccenaic hypertrOphy
Concenaic hypertrophy
Nonnal venaic1e
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TABLE 3.2: Baseline characteristics of the transplanted patienlS
Transplant
Recipients
(0-143)
Age (yean) 37 (35,39)
Female 31%
Diabetic 20'10
Ischemic heart disease l 4.9%
Hean failure 15%
Hypertension> 10 yearsb 26%
Smokers 35%
Duration ofdialysis prior II (1,21)
to transplantation
Continuous variables an:: expressed as mean (95% CI). dichotomous variables as
percentages. a. Ischemic heart disease was defined as a history of myoc::ardial infarctKm.
coronary rcvascularization. or angina. b. Hypcncnsion was defined as blood pressure >
140190 nunIHg
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Figure 3.1: Fate of patients in the transplanted cohort
29
termination) before a subsequent echo was scheduled (Le. within a year of the previous
echo). The median times to echo and reasons for not having a subsequent
echocardiogram are summarized in Figure 3.1.
Chalfges in L V moss and volume: In the 70 patients with two echcxardiograms. LV mass
index decreased from 161 (95% CI145,177) ymJ at one year to 146 (134,159) g/m2 at2
years following transplantation (Bonferroni corrected p9l009, Figure 3.2a). There were
no further clinically important or statistically significant changes in l V mass index in
years 3 (n;:4(}) and 4 (n=18) (Figure 3.2b-c). LV cavity volume index decreased from 81
(72,91) mUm2 at I year to 75 (68. 82) mUm2 at 2 years (paired t-test, n"70, Bonferroni
corrected p=(l.05). No further changes were seen in years 3 and 4 (Figure 3.3a-c).
Predicting changes in LV mau index: Using change in l VMI as the outcome variable.,
the impact ofsevera.l potential predictor variables (Table 3.1) was assessed using multiple
linear regression. Three of70 patients had missing baseline data and were not included,
leaving 67 patients available for analysis. The resultant model suggested that older age,
duration ofhypenension, number ofantihypenensive medications required. low pulse
pressure and l V morphology at baseline were independently and significantly associated
with failure of regression of LVMI from year I to year 2 (p<O.OOOOO3. R2=O.44).
Because the impact of pulse pressure seemed counterintuitive (low, as opposed to
high, pulse-pressure was associated with a failure to regress), we tested for an inter.te:lion
between ventricular morphology and pulse pressure. Th.is interaction was highly
significant (p=O.OO7). The model incorporating the interaction was highly successful
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Figure 3.3b: Change in LV cavity volume from 2nd
to 3rd echo (n=40)
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Figure 3.3c: change in LV cavity volume from 3rd
to 4th echo (n=18)
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(p<O.OOOOOI. R1 ~.S2) (Table 3.3), accounting for sr" ofthe total variation in the
change in LYMI .
Table 3.4 illustrates the interaction between ventricular morphology, duration of
hypertension. and pulse pressure. In patients with normal hearts at year I, the model
predicts very liule change in LVMI in those with shon duration of hypertenSion, while
patients with longstanding hypertension experience on average quite a dramatic increase
in LVMI. Increasing pulse pressure is associated with increasing mass over the interval
studied. and.seems to identify ventricles at increased risk for progression. At the other
morphological extreme, in patients with eccentric LVH, the absence of longstanding
hypertension defines a subset ofvenaicles capable of regression. Dilated hearts in
patients with longstanding hypertension do not regress, on average. The relationship
between pulse pressure and change in LVMI is reversed compared with the situation in
normal hearts: high pulse pressure is a marker for greater regression. Patients with
concenaic LVH showed behavior intennediate between these poles. A biological
interpretation of these findings follows in the discussion.
Time·averaged hemoglobin and serum creatinine. albumin, calcium, and
phosphate were not predictive of regression in either univariate or multivariate analyses.
Similarly, duration ofdialysis prior to transplantation, history ofclinical congestive hean
failure or ischemic bean disease, c)"dosporine therapy, and class of antih)'pCrtCnSive
agent (angiotensin converting enzyme inhibitors, calcium channel blockers., beta·
blockers, diuretics and other) were not significant predictors of changes in LVMI.
Because previous studies in the general population have shown that different classes of
antihypertensive agent have differing effects on regression LVH, we attempted to force
J7
Table 3.3: PrediclOrSofchange in LVMI in rcnaI uansplant recipients who
bad an echocardiogram in both the first and second years post
transplantation (N=67). as identified by multiple linear regression analysis.
Predictor
Overall model
Coefficient P-vaJue
0.000001
Age +0.97 g1m1 per year
Duration of +35 glm1 for duration> to 0.008
hypertension years 0.0002
Number of medications +24 g1m2 for> I 0.009
antihypertensive
Pulse pressure
+1.1 g/m1 per mmHg
+14g1ml ifprc:sent
+IOOf/m1 ifpttSeflt
LV morphology
Nonnal ventricle
Concentric
hypertrophy
Eccentric
hypertrophy
PP x LV morphology -1.13 glm1 per mmHg if
PP concentric present
LVH .3.2 g/m1 per mmHg if
PP x eccentric present
LVH
o.cxn
a Individual p-vaJue:s for variables are not meaningful in the context ora significant
interaction between them
J8
Table 3.4: Predicted change in LV mass between first and second echo as a function of
LV morphok»gy, duration ofhypenension, and pulsc: pressure.
Left Ventricular Duration of Pulse Pressure*
Morphology Hypertension
39mmHg 44mmHg S3mmHg
Nonnal SlOyc~ +Sw'ml +IOg/ml +lOglml
(n=18)
>10 years +40glml +4Sgfm l +S4gtml
Concentric slO years .2Sglml .2Sy/m1 _26g1ml
hypertrophy
+9g1m1(n=21) >10 yean, +9g1m1 +9y/m1
Eccentric SIO years .20glm1 .30g/ml -48g1ml
hypertrophy
+4g/ml
_12g1ml(n=28) >10 years +ISglml
*Pulse pressUJ'e"Z mean systolic blood pressure·mean diastolic blood pressure in the inter
.echo interval.
3.
the inclusion of antihypertensive class in the equation. llUs did not improve model 6t
(p>O.8) and 50 was deleted from the model [121.123]..
3.4 DistUSli..
Changes in L f'StruClUre: The primary aim of this study was to describe the long-tenn
impact ofrenal transplantation on cardiac hypertrophy in a large. prospectively followed
group of transplant patients. Seven! investigators have analyzed prc- and post-
transplantation changes in cchocardiographic parameters [36, 124·131 but with the
eltccption ofone study (36]. these reports have involved small numbers of patients,
limiting the power and gencralizabilityoflhe results. rn a previous publication from this
cohort (36]. Parirey et aI. demonstrated that significant improvements in ooncentric LV
hypertrophy and LV dilatation occur following renal transplantation. observations
consistent with those made by other investigators (124-131]. The key finding in the
present study is that regression ofLVH continues beyond the first post-transplant year,
reaches a nadir at approximately two years and appears to stabilize in the third and fourth
years after transplantation. To our knowledge. this constitutes the first description to date
of changes in cardiac hypertrophy occurring in the later phases of renal transplantation.
Several limitations to these observations bear discussion. Although OUI sample
size was initially large. there were significant losses 10 fallow-up over time. as one would
expect. As a consequence. the precision of the estimates ofchange in LYMl is less for the
later than the earlier echocardiograms. Because cchocardiography was scheduled
regularly in all patients, it is unlikely that the losses to follow-up resulted from
ascertainment bias. However. it could be argued that since l.VH is a risk factor for
morbidity and death. patients with severe l.VH might have been lost preferentially
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because ofearly death or graft failUJe. biasing the results towalds a decline in mean LV
mass index. Several observations suggest that this did not happen, however. First, death
caused no losses to follow-up after the year-I echocardiogram. Graft failure resulted in
the loss ofonly 2J113 patients (1.8%) between the firu and second year, 3/70 (4%)
patients from. year 2 to 3, and no patients between year 3 and 4. These small percentages
are unlikdy to substantially bias the results. Most of patient losses (75/95& 80%) were
due to censocing at study tennination. This high rate ofcensoring occurred because
although median follow-up for the cohort was 4 years from initiation ofdial)'5is.
transplantation occurred after a median wait of one year. Theoretically 50-;' ofthc
original cobon should have been censored by 3 years from transplantation. We observed
531113 slUdy-end censored events between lhe first and last echo, or 47%. vcryclosc to
the expected value. Finally, (he pattern of regression over time was similar in patients
wilh two. three and four echocardiogtams, suggesting that the observed changes were
independent offollow-up losses.
lde,uification ofrislefacton for progreMion!regress;o,,: Despite the overalliendency to
regress, not all patients in this study regressed to the same degree, and some progressed.
Moreover. in 39% of patients LV mass index failed to nonnalize even at four years [38}.
Since LVH is known to confer an adverse prognosis12[32,47,1321, we attempted to
identify risk factors for progression using multiple linear regression. We developed a
highly significant predictive model for changes in LVMI between the firsl and second
plSI transplant year. Age. LV morphology and three independent markers of"pressure
overload" (duration ofprioc hypertension, number ofanlihypertcnsives required, and time
averaged pulse pressure) were found 10 be important. Moreover, the interaction between
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LV morphology and pulse pressure helped unravel somcofthe contradictions thai
emerged regarding the role ofbkxld pressure as an adverse cardiac prediclor.
The direction and strength ofthe association between a putative risk factor and an
outcome can only be properly estimated when !he risk factor is measured before the
occurrence ofthe outcome. This requirement is ofeven greater importance whenever the
outcome can modify the risk faclor, a phenomenon called "reverse causality". Since poor
ventricular function can cause low blood pressure. !he inclusion of palicnts wi!h
significatu heart disease, even in a prospective study, may confound the ttue relationship
between blood pressure , LV morphology and monality. [n large, populalion based
slUdics such as the Framingham Cohort (83,132], in which die inception cohort is mostly
free ofdisease, confounding by reverse caLlSalily is less importanL In mosl renal cohorts,
however, hean disease is often prevalent at the time hypertensive risk is assessed. Levin
ct at have shown that 2J-1o of patients with mild renal insufficiency (CCr SG-75mUmin)
already have LVH by cchocardiogram, and that this proponion grows to 45% among
patients with severe CRJ (Cer < 2S mUmin) [23]. In the prcsenl cobort, 80% ofpalients
had some fonn oflVH at !he start ofdialysis [32]. In this setting, confounding by revCfSC
causalily is not only possible, it is likely.
One of the strongest prediCIOrs of non-regression in the present study was the
presence of longstanding hypertension. This relationship held ttue independent oflhe
relatively complex inleraction between pulse pressure and l V morphology. The need for
multiple antihypenensive medications, a crude indication of severity of hypertension, was
also independently associaled wi!h increasing l VMI. These observations arc consislent
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with the hypothesis that hypertension is an adverse cardiovascular risk factor in renal
transplant patients.
AJthough the individual values ofsystOlic and diastolic OP were not
independently associated with change in LVMI, the difference between the two, the pulse
pressure, was. However, the pulseprcssure data must be interpreted in light of the LV
morphology, since there was a highly significant interaction between the two. In patients
with nonnaI hearts., increasing pulse pressure was associated with increases in LVMI.
This is compatible with thc bclieflhat pulse pressure in patients with normal hearts may
be a reflection of systemic 3f1erial compliance, which in tum may be causally related to
increasing LV mass (24].
In contrast. in patients with dilated ventricles, high pulse pressure was associated
with regression of hypertrophy. It is possible tha1 in these patients, pulse pcessurc may be
a marker for a reversible cause ofeccentric hypertrophy, such as volume overload from
fluid, anemia, or a patent arteriovenous fistula, abnonnalities which may subsequently
resolve. Data on fistula patency at time of transplantation was not available. Detailed
infonnation was available fOf anemia, which did not seem to predict pulse pressure very
well and could not successfully be substituted fOf it in the model. The exact meaning of
pulse pressure in this setting remains unresolved. In any case, pulse pressure seems to be
a reflcction of underlying hemodynamic relationships rather than a causal factor for LV
mass regression. This observation reinforces the point that blood pressure measurement at
or ncar the time ofoutcome assessment may lead to associations confounded by reverse
causality.
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The impact ofventricular morphology by itselfdeserves further scrutiny.
Nonnal-size hearts arc small and compact by definition, and can only grow larger or
remain the same size. They cannot grow very much smaller. It is not surprising, therefore,
that nonnal hearts in this study were eitberobserved to grow, or 10 stay the same size. In
contrast. hypertrophied hearts are by definition large and heavy. Growth is possible if the
hypertrophy is mild, but not ifsevere and al the upper Iimil of the physiologically
possible. Regression is theoretically always possible. Thus, hypertrophied hearts wen:
observed, on avmge, to regress.. II is likely that the phenomenon of-..egression to the
mean" contribuled 10 these observations. II would be hazardous to infer thai increasing
LVH ''promotes'' regression. However, it seems reasonable to say that hypertrophy does
not appear to pmclude regression. None oflhese considerations invalidates the primary
rationale for including ventricular morphology as a covariate, which was to see whether
the impact of other variables might differ according to baseline LV morphology.
No relationship between type of amihypertensive agent (particularly ACE
inhibitors) and change in LVMI was seen in this study, in conb'a5t to observations in the
general population (121-123]. AJthough this may reflecl a true diffemx:e between renal
transplant palients and the general population, the possibility ofa Type 2 error (failure to
rejecl the null hypothesis) musl be considered. Our results should not be interpreted as
definitive evidence against !he existence of class specific effects of antihypertensives on
regression of LVH in renallran$plant recipients. Furthc" study is required to answer this
question.
Limitations of the Analysis: Multiple linear regression is powerful and sensitive., but not
infallible. Our sample size was sufficient to generate a model with up to 12 explanalory
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variables. It remains possible, therefore, that a larger sample might have uncovered
additional associations between the excluded variables and changes in LVMI. This
possibility may be particularly relevant in the case of type ofantihypertensive agent class.,
as discussed above.
In any multivariate analysis, the relationships unoovered are not necessarily
causal. Causal inferences must be made in light of biological plausibility, which
introduces a subjective component to the analysis. Furthermore. our explanatory analysis
was partly data·led, and may be less reliable than a purely hypothesis led analysis. The
observations made in this portion of the analysis, therefore, should be interpreted as
hypotheses generated by the data rather than proven by the data. Despite these
limitations, the signi6cance and explanatory power of the model developed are
considerabk.
3.5 Coatlusw.
Regression of LVH seems to continue beyond the first year after renal transplantation.
reaching a nadir at rwo~ and persisl:ing into the third and fourth post-transplant yellS.
Failure to regress was associated with older age, longstanding hypertension, need for
more than one antihypertensive agent, high pulse pressure in patients with normal hearts
and low pulse pressure in patients with dilated venuicles.
CHAPTER 4
RISK FACfORS FOR AND OUTCOME OF DE NOVO CONGESTIVE HEART
FAILURE AND ISCHEMIC HEART DISEASE IN RENAL TRANSPLANT
RECIPIENTS: A RETROLECTIVE COHORT STUDY
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".1 l.trodltCtioa
The incidence ofcardiovascular disease (CVD) among renal transplant recipients (RTR)
is 3 to 4 fold greater than that observed in age-matched control populations. making it the
major cause ofdeath among RTR [3,4). This apparent surplus risk is potentially
attributable to th1eerisk factor categories: I) Traditional cardiac risk factors (as identified
by the Framingham Study) such as age, gender, diabetes.. hypertension. hyperlipidemia.
and smoking [5], many ofwhich may be adversely altered by renallransplantation 2)
Risk factors related to the transplant state and its complications such as
immunosuppression, cyclosporine vascular toxicity, graft rejection, and viral infections
(e.g. cytomegalovirus). 3) Risk factors related to loss ofgraft function such as anemia.
salt and water overload, and hyperhomocysteinemia. lbe manifestations of cardiac
disease in RTR include both IHD (e.g. Ml, angina pectoris) and LV functional disorders
(CHF). Both CHF and nm are important adverse prognostic markers in the general
population. In dialysis patients. CHF is a more important pn:dictor of mortality than rno
[32J.
An examination ofcardiac disease in RTR should ideally explore the risk factor
categories listed above in relation to both CHF and lHD. Although CHF is likely a
significantl110fbid complication in RTR as it is in dialysis., no studies to date have
explored the rislc factors for and outcomes ofCHF in the renal transplant setting.
Furthermore, while several studies have examined IHO in RTR, few studies have
employed multivariate techniques to compare different risk categories, and only one
study has examined exclusively de novo events in order to limit the confounding
innuence of pre-transplant cardiac disease [4,6-9). No study has examined the relative
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prognostic impactofCHF vs. am. We thereforecondueted a retrolcctive cohort study in
a single Canadian centO'" in order to 1) describe the risk factors for and intendarionsttips
between de DOVO CHF. de novo mo, and monaliry, and 2) assess the relative importance
ofdifferent risk factor categories in the evolution of de novo cardiac disease in RTR.
4.ZMnhd$
We pcrlonned a retrolective cohort study on all 77S consecutive adults receiving a renal
transplant in Manitoba between 1969 and 1999. Due to the relative geographical isolation
of the region, all transplanted individuals were followed exclusively at a single center in
Winnipeg, Manitoba. It has been a policy of the Manitoba Transplant Program since
inception to atthive all c1inic:a.l. and hospital records. including procedure and laboratory
reports. As a result, detailed clinic and hospital records were available for 98% of
patienlS. Data on baseline demographic. clinical. and outcome variables were abstracted
from a review of all inpatient and outpatient records. The detail available pennilled the
systematic application ofa priori definitions for several outcome variables. enhancing the
validity of the analysis. The completeness, detail and reliability of the data available
significantly decrease the limitations inherent in retrolective (vs. prolective) data
acquisition.
Baseline Variables: All data were obtained from inpatient and outpatient records by
research nurses trained and supervised by Dr. Rigatto. Age. gender. presence or absence
of diabetes, living or cadaveric donor. and smoking sta1US, were all abstracted from the
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pre-transplant assc:ssmenL lsc:hemic heart disease (llID). congestive heart failure (CHf),
and peripheral vascular disease (PVD) were judged 10 be absent at baseline if the p~
transplant assessment concluded !hey were abscnL Cardtovascular disease was a focus of
the pre·transplant assessment protocol. and diagnosis was based on oral mSlOfY. records
review. physical examination and EKG. with funher testing reserved for symptomatic
individuals or diabetics older than 45 years. We did not review records prior to
lransplantation. The definitions of IHD and CHF as outcome events after transplantation
are more precise and given below. Hypertension was defined as blood pressure >140190
mmHg or need for antihypertensive therapy. Era of transplantation was defined as
IranSplantatiort before or after 1985. the year in which cyclosporine was added to
azathioprine and prednisone for routine maintenance immunosuppression. Prior to 1985.
the majority of patients received azathioprine and prednisone alone. Pre-emptive
transplantation was defined as transplantation at time of progression to end-stage renal
disease (ESRD) without a "bridging" period on dialysis. Delayed graft function was
defined as need for dialysis in the first two weco after renal transplantation. Acute
rejection was defmed as an acute rise in serum creatinine of at least 10-/. not attributable
to pre-renal causes, obstJuction, or cyclosporinc toxicity and treated with pulse steroids
and/or anti· lymphocyte prepan.lions. Systolic and diastolic blood pressure. hemoglobin,
albwnin and senun creatinine were measured at least quanerty per clinic protocol. while
total cholesterol was measured yearly.
Outcome Variables: An episode of ischemic heart disease (nID) was defined as
hospitalization for acute myocardial infarction (admission with chcst pain accompanied
by charxteristic EKG changes of infarction or a J-fold elevation in CK) or
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revasculariution (coronary artery bypass grafting or pen:ulaneous translwninal
angioplasty). Chest pain was not included in the definition because it is a less specific
marlc.er of mo. De nOl'O mo was defined as mo occurring for the first time in a patient
previously free of mo. Recurrent nm was defined as a subsequent episode of nm in a
patient having had a previous episode of mo. Congestive hean failure (CHF) was
defined as dyspnea plus two of the following: raised jugular venous pressure, bibasilar
crackles, chest x-ray evidence of pulmonary venous hypertension or pulmonary edema.
De novo and recurrent CHF were defined as for rno above. Cardiovascular death was
defined as death from myocardial infarction or a revascularization procedure, cardiogenic
shock., primary anbythmia, stroke, or ruptured aortic aneurysm.
Nonnally distributed continLK>Us variables are expressed as mean (SO), non-nonnally
distributed variables are expressed as median (range). Dichotomous variables are
expressed as percentages. Outcomes are described using event-free survival curves
generated by the Kaplan-Meier method. Patients were censored at graft failure, latest
follow-up, or death, except where death was the endpoint being analyzed. The unadjusted
influence of each predictor variable was assessed using univariate Cox proportional
hazards regression. Multivariate Cox modeling was used to adjust for the simultaneous
influence of several variables. Backwards conditional stepping operative on the complete
variable pool was used to select the "'best" multivariate model. Appropriate additional
tenns were used to test for interactions or curvilinear relationships. The assumption of
proportional hazards was checked by visual inspection of the logt:-Iog) transfonned
survival curves, which proved acceptable in all cases. The variance inflation factor (VIF)
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was used to screen for problems of multicollinearity among the variables: no variables
required elimination liom the pool for lhis reason. For the analysis of de novo events in
patients alive and free ofcardiac disease at one-year. values for SBP. OBP. hemoglobin,
creatinine., Gault.Qxkroft eteaIinine clcannce, and albumin w~ avenged over the first
year for each palicnt. If more !han one total cholesterol level was available in the first
year. !hese were also averaged.
Missing values: Missing values for continuous variables were randomly imputed
assuming a norma! distribution of missing values having the same mean and standard
deviation as the known values. Missing values for dichotomous variables were randomly
imputed assuming a binomial distribution of missing values having the same probability
of being lor-a as the !mown values [133}. The proportion of values randomly imputed
were as follows: cholesterol 35.3%, smoking 20.".4, albwnin 10.8'1.. blood pressure
9.1%. hemoglobin 8.9% and creatinine clearance 4%. All other variables were complete.
The robustness of the imputation method was assessed in two ways. First. the random
imputation procedure was repeated four times and the analyses repeated using each set of
imputed valuC$. Tbe final models were vCfY similar to each other, suggesting that random
imputation had lillie impact on !he results. As an additional chedc.. multivariate nonnal
imputation was used (134). The models gcncralcd again were VCfY similar. confinning
the robustness of the results. Wbcrc relevant, the effect of the imputation method on
model parameter estimates is discussed in the text.
4.3 Results
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There were 775 consecutive adult renal U'anSplants perfonned in Manitoba between Nov
29, 1969 and Jun I, 1999. Table 4.1 summarizes selected demographic and transplant
related characteristies of this cohort. Although the ttansplanl patients represented a select
group with generally low comorbidity, three quarters wen: hypertensive prior to
transplantation, over half were smokers and one fifth had had a prior episode if DiD or
CHF. Median survival for the group, estimated using the Kaplan-Meier method was 18
(13,22)~. Median deatfl..unsorcdgraft survival was 15 (1 1,20) years. Ninetypcrt:ent
were firsltransplants.
Impact ofbaseline cardiovascular disease
As expected, presence of cardiovascular disease at baseline was associated with
cardiovascular death (Table 4.2). When the distinct impact of IHD and CHF was
examined. notcworthy trends appeared. The point estimate of the R:lative hazard in the
multivariate models was similar for both IHD and CHF. Both appeared to confer a 60-
70% increase in risk: of CV death, although the confidence interval for CHF was wider,
and the result not statistically significant. When both IHD and CHF were included in the
model, baseline IHD was selected over CHF. suggesting that IHD is the stronger
predictor of cardiovascular death. This is the reverse of the relationship in dialysis
patients where CHF is the stronger predictor of death (see discussion). Cardiovascular
disease was less strongly associated with all cause death, as expected. The risk. associated
with CHf was greater for this endpoint and the confidence interval tighter in comparison
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with nm, although both int:ervals crossed unity. Overall, cardiovascular disease was a
significant but not overwhelming predictor ofearly death.
The derivation of the de novo cohort is iIIustr.lted in Figure 4.1. In all, 473 of the ns
palients were alive and free of cardiac disease: at 1 year. Baseline: characteristics and
average clinical and laboratory variables in the first year are summarized in Table 4.3,
and are broadly similar to those of the overall cohan.
Over a median follow-up of 7 (4,12) years (1Ota1 follow.up of 4235 patient·yc:ars), 51
patients developed de novo CHF, for an average incidence rate of 1.23 events! 100
patient·yc:ars. The: univariate predictors of novo CHF were age, diabetes., declining renal
function, low albumin, higher blood prc:ssure, and cadaveric donor (Table 4.4). The:
multivariate analysis reinforced the importance: of age, diabetes., serum albumin and even
modest elevations in diastolic blood pressure (Table 4.S). Gault.cockroft creatinine
clearance and donor type were replaced in the multivariate model by hemoglobin, DGF,
and gender. This is not surprising when one considers that hemoglobin and CCr were
significantly c:orrelated (Figure 4.2), and that OOF, hemoglobin and gender were all
associated with CCr (Table 4.6) in a multiple linear regression model. The: causal
implications of these associations are discussed later.
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Consecutive adults transplanted
(n-775)
I -----+1 Death or graft failure <I year
(n-167)
Alive with functioning graft at 1 year
(n=608)
Clinical hean disease at baseline
(n:ll117) or in the first year (n::: 18)
I::0o.r cardiac dl;;;;.o at I yoar ]
(0=473)
DE NOVO
HEART DISEASE
Figure 4.1: Source of the cohort analyzed for de novo heart disease
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Table 4.3: Baseline characteristics l of473 renal transplant
patients in the de novo cohort
------
A8' 39 (12) years
Female 42 %
Diabelic IS ~.
Smokers~ 55 "I.
Duration of dialysis I (0.5,2) years
Pre-emplivedialysis 8 %
Transplanted> 1985 61 %
Cadaveric donor 81 %
Delayed graft funclion 26 "I.
Cyclosporine regimen
"
~.
Rejec.lionsin firslyear 2 (1,4)
Syslolie BP 139 (16) mmHg
Diastolic BP 81 (8) mmHg
Crelltinine 160 (61) j.lntol/L
cc, 58 (19) mUmin
Hemoglobin 124 (19) IlIL
Totilichoicsterol 6.4(1.4) mmoVL
Albumin 38 (4) IlIL
I. Cominuous variables expressed as mean (SD) or median (interqLlllr1ile range) for lhe
tohor1ll1 appropriate. Cltel;'Oritll variables arc expressed as pertenlages. Time
depcndcntvariablesareavcrl~edovCflhclirsl}'Car.2. WilhinS)'Cllrsof Iransplan.
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1bc: crude survival of patients who developed de novo CHF vmus those who did not is
illustrated in Figure 4.3. Development ofde novo CHF was associated with a 70"1e greater
risk: ofdeath independent orage and diabetes (RR 1.70 (1.06, 2.71».
Fifty·three patients developed de novo IHD over the observation period. for an average
incidence rale of 1.25 events 1100 patient.years. On univariate analysis (Table 4.7), age,
gender diabetes and both systolic and diastolic blood pressure were significant predictors
of de novo IHD and these associations persisted in the multivariate analysis. The
presence ofat least one rejection episode during the fim year was also found to increase
risk in the multivariate model (Table 4.8).
The relationship between blood pressure and de novo IHD was significantly improved by
incorporating a quadr.1tic SBP term in addition to linear diastolic and systolic terms.
(Table 4.9). This quadratic term was highly significant. Figure 4.4 illustrates the
curvilinear relationship between SBP and adjusted risk (relative hazard). SBP below 130
mmHg and above 160 mmHg appear to be associated with increased risk ofde novo lHD
(J-curve phenomenon). 1be power of the study was insufficient to establish both
thresholds explicitly and precisely. An SBP<130 appears to be associated with a relative
hazard of 2.48 for lHD (Table 4.8). When the blood pressure was excluded from the
model. serum cholesterol was substituted (Table 4.10).
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T.blt 4.7. Univariate risk raclors for de novo IHD as determined by Cox regression.
Variable l
Ap(ye.n)
F,••I'l'llder
D.....n
Smokc:rl
~.Iininc CIt.IlI,," (mUminr'
Hemoglobin (Ill)
TOl.lcholcslnol(mmoIlL)
Albllmill(lIl)
Sy"lolklllP(mmlla)
O'-t"le It t"'.'1&1
Tr.mpl.nlcd>19U
Anylc\llerejcclillllin rlTSl 6monthl
OcloycdJl'.t1: r\lllC1ion
CadavniedOOOf
CyclosporilMl\l~
Ourationordi.l~iI
Prccmpli...etronlplllnialion l
Rcllli...c riskl (95%Cll
1.04 (1.02,1.06)
Ooll (0.1"0.67)
UJ (1.n.1.07)
0.90 (0.52.l.j3)
0.91 (0.97,1.0009)
1.00 (0.99,1.02)
1.16 (0.96,J..41)
0.97 (0.90,1.03)
1.02 (1,004,1.04)
1.06 (I.02,U')
0.9S (0.s3,1.71)
2.57 (0.&0,8.24)
1.0) (0.H,1.931
2.19 (0.93,S.12)
0.99 (0.55,1.79)
1.00 (0.89,1.14)
0.71 (0.22,2.27)
..-
....,
1.-
0.'
0."
0.'
0.1
0.3
0.01
0._
0.'
0.1
0.'
0.07
1.0
0.'
0.'
I. ConlmUOlII i.blcs ...c ....tr.acdo\'erltlcfir1t y<:1II pall tr....plllll.. ion 2. Eapl"et.ropn\lniteh.nlcln
conlin\lOUl i.bIn, e,g. ror diulolic 0", RR- 1.06 ror Cllch mmHI incrcmcm. 3. PIlII or CIllUnl lmoller 4.
Gaull·Cockroft cilimaic. S. Ne...er dioly~ed,
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Table 4. 9: Risk factors for de novo IHOI: Incorporation ofquadratic relationship
with systolic blood pressure.
Variable RellltiveRisk P-villue
Age (years) I.O~ (1.02,1.08) 0.0001
Diabetes 4.01 (2.00.8.04) 0.0001
Malegcndcr 3.17 (1.45.6.95) 0.004
Diaslolic blood prcssurcl 0.006
per mmHg increase 1.06 (1.02.1.11)
Systol~ blood pressurel 0.003
per mmHg increase 0.96 (0.94.0.99)
per (mmHg)2 increase 1.0007 (1.0002,1.001)
Any rejection <I yr 3.)) (1.02.10.8) 10.046
I. IHD-Myocardial inrarction or revascularization. 2. Average diastolic blood
pressure over the first year post transplantation. 3. Quadratic (curved) relationship
with SOP.
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Table 4.10: Multivariate risk factors for de novo IHO: Blood pressure excluded
from model.
Variable Relative Risk P·value
Age (years) 1.04 (1.01,1.06) O.(X)I
>40 years 2.19 (1.26,3.79)
Diabetes 4.33 (2.39.7.83) 0.ססOO5
Male gender 3.06 (1.46,6.39) 0.003
Rejections in first year 3.61 (1.11,11.8) 0.Q3
Total cholesterol 0.03
pcrmmoUL 1.24 (1.02, LSI)
I. Average diastolic blood pressure over thc first year post transplantation.
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The Wladjusted survival curves of those who did and did not devdop de novo IHD are
shown in Figure 4.5. Development of de novo IHD was associated with a 74% greater
risk ofdeath independent of age. diabetes, and gender (1.74 (1.19,2.54».
Cause of death and monality rates in the de novo cohon are summarized in Table 4.11.
Overall mortality was low, with approximately 3 deaths per hundred patient-years of
observation. Half the deaths wen: from cardiovascular causes.
The univariate predictors of all-cause death after I year are shown in Table 4.12. The
impact of age, diabetes, high blood prc:ssun:. and delayed graft function persisted after
multivariate adjustment, while an independent association with anemia was uncovered
(Table 4.13). Modest elevations in SSP (>130 mmHg) and modest reductions in
hemoglobin « 120 gIL) appear 10 be associated with increased monality risk.
Mullivariate ptedicrors of cardiovascular mortality were age. diabetes., high blood
pressure, high cholesterol. and cadaveric donor (Table 4.14). Multivariate predictors of
non-cardiovascular mortality were age, anemia, systolic blood prcssW"e, and Jow total
cholesterol (Table 4.15).
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T.ble 4.11: Causes ofdeath in the de novo cohort.
Cause of death N % Rale f 100
patient years I
TOlal 118 100 3.14
Cardiovascular 59 50 1.57
Infection 22 19 0.60
Malignancy 20 17 0.53
Other 17 14 0.44
I. Averaged over tOlal follow-up of 4235 palient yeal'l
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T.ble 4.12: Univariate risk factors for all-cause mortality as detennined byCox
regression in the de novo cohort.
Variable
Aae(ycan)
Fcmalcgcndcf
DlaDctes
Smo",,'
CnlllnlncCIClnnee(mUwlln)l
Ilcmoslobin(alL)
Tocil CbolCSltfol (mmoVL)
Albumln(&fL)
S)'1II.wc b&Nd prnlure (mrnHJ)
INlfielic blood prtllUn (mmHI)
Tl1ll1pll.nlro>1985
Any lCulercptionIn firsl 6monlhl
DtllycdCraflfUndlen
Cadlvcrkdonor
Cycl05porincusc
IJI.lrationofdialystl(ycars)
Precmpliyclranspbntllion'
Rclaliyc Riskl (95%CI)
1.05 (..... l.O1.
0.77 (0.S2,1.14)
1.92 (1.93, ••41)
1.01 (0.70,1.45)
0.99 (0.91,0."1)
1.00 (O.99,UlO6)
1.11 (0.97.1.26)
0.95 (0.91,0.99)
"'3 (1.81,).(M)
1.04 (1.01,1.116)
1.21 (0.86.1.90)
1.45 (0.78,2.70)
1.64 (1.11,1:.41)
3.79 (1.14,1.79)
1.40 (0.93,2.13)
1.06 (0.99,1.13)
0.86 (0.•2.1.77)
P'Ylluc
0.ססOO5
0.2
0.ססOO5
0.'
0.02
0.'
0.1
0.01
'.lltOO5
0.8082
0.2
0.2
0.11
0._
0.1
0.1
0.1
I. Expressed per unit change in continuous varillbtes, e.g. for DBP, RR- 1.04 for each mmHg
increment 2. Pasl or current smoker 3. Gauh·CockroR estimate. 4. N~VCf dialyzed.
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Table 4.14: Multivariate risk factors for cardiovascular mortality as determined
by CO)t regression in the de novo cohort.
Variable Relative Rilk'·l P·value
Age (yelfl) 1.06 (1.03,1.08) O.OOOOS
>40 years 2.95 (1.68,5.18)
Sysloliebloodprc:5surc:
per mmHgmcrc:ase 1.02 (1.001,1.03) I"~forSOP>14S nmlHa 2.23 (1.27,3.90)
Di.bc:ICI 4.56 (2.47,8.44) 0.00005
Tot.leholCiterol
per rnmoUL incre.se: 1.)7 (1.14,1.64) 10.0008
>5rnmolll 2.15 (1.12,4.10)
Cadava-iedonof 5.60 (1.23,25.4) 10.02
I. Expressed per unit change in continuous variables 2. Continuous variables
averaged over first year
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Table 4.15: Multivariate risk factors for non-cardiovascular mortality as
detennined by Cox regression in th de novo cohort.
Variable Rc'-tiveRlskl,J '·value
Ai,,<=(yearJ) 1.04 (1.02,1.06) 0.0006
>«l 2.07 (1.22,3.49)
Hemoglobin
peraVLdccreasc 1.02 (1.001,1.03) 10.03
HIb<IOOgfl 2.73 (1.31,5.70)
S)'5lolkblood prenure
pernunllllincreaH 11.02 (1.001,1.03) 10.03
>130mmHg 2.23 (1.09,4.57)
TOIalchokslerol
pet' nunolll incrUH 10.82 (0.69,0.98) 10.03
<5.5mmoIlL 2.13 (1.26,3.61)
1. Expressed per unit change in eOnlinuous variables 2. Continuous variables
averaged over first year
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A small number of retrolective cohort studies have examined risk facton: for cardiac
disease and death in renal tr.msplant patients [4.6-9]. The present cohort study
distinguishes itself from the pnceding studies in several ways. This is the first study 10
examine the risk factors for and impact of CHF in RTR. Only de novo events occurring
after I year were studied in order to lessen the confounding effect of pre..cxisting cardiac
disease and pre-tr.msplant risk facton on the associations between post-transplant
variables and OUICOmes. Finally. a broad spectrum of putative cardiac risk factors.
comprising many traditional. renal failure-related and transplant-related variables. were
analyzed using multivariate techniques operating on the complete variable pool. Since
several risk variables are highly conelalcd, discerning the independent effect of these
variables requires simultaneous modeling. The outcomes and risk factors identified in this
study arc discussed below.
Both de novo DiD and CHF were harbingers of early death and were independent of age.,
gender and diabetes. When both events were included in the model with age. gender and
diabetes., de novo nm remained significant whereas de novo CHF did nol. De novo urn
thus appears to be the stronger predictor of all cause mortality, in contrast to studies in
the dialysis population. where CHF is a stronger predictor of mortality than mn [41.45}.
The major caveat to this interpretation is that the survival analysis used graft failure as a
censoring endpoint. De novo CHF was strongly and indcpc:ndenlly associated with graft
loss and the combined endpoinl of graft loss or death (data not shoWTI). Moreover,
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Harnett et aI. [41] have shown that CHF prior to or at the initiation of dialysis is a
powerful independent predictor of subsequent death on dialysis. It is likely, therefore,
that the full adverse impact of CHF may only be discerned after patients with graft failure
have returned to dialysis. Since events after return 10 dialysis wen: not included in this
analysis, the observed impact of de novo CHF on patient survival has likely been
underestimated in the present study.
Riskf.euwsftw HI' U ..... CHF ."tlIHD
Non-modifiable risk factors: Age and diabetes mellitus were independently associated
with adverse cardiac events and death in the present study. Diabetes was not predictive of
non-cardiovascular death, consistent with the notion that the mortal impact of diabetes is
mediated primarily via cardiovascular complications. lbese results 1m entirely consislent
with the large body of evidence in the general, dialysis and transplant populations [4-
6,8,9,78,13.5}.
Male gender has been associated with elevated risk. of IHD in the general population and
in the renal transplant population [4-6,9,78,13.5}. Our study suppons this associalion.
Interestingly, female gender was independently associated with an increased probability
ofde novo CHF. An association between female gender and CHF bas also been found in
dialysis patients (40). It is possible that female gender is causally related to CHF because
of some gender specific trait not accounted for by the other covariates in the model. On
the other hand, female gender, hemoglobin, and delayed graft function, among olhers,
were predictive of CCr under a linear regression model, so thai it is possible that these
three variables in combination may be surrogate rn.arken for poor renal function. nuid
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overload. and consequent CHF. Which of these possibilities is true cannot be determined
by the present analysis. We did not find any independent association between gender and
mortality.
Blood pressure: Hypertension has been clearly established as a risk factor for DiD, LVH
and CHF in the gcncnJ population (5,38,83). It is a risk factor forbolh LVH and CHF in
dialysis patienlS [47). In the present study, DBP was a powerful predictor of de novo
CHf. SBP could be substituted for DBP wilh no loss of predictive power in the model.
High SBPs were independently associated with all-cause and cause-specific mortality. In
these cases, SBP could be successfully substituted by DBP without loss in the predictive
power of the model. In all cases, excess risk could be observed even with modest
elevations in systolic or diastolic blood pressure.
In the case of de novo DiD, we found a curvilinear (J curve) association between blood
pressure and outcome (Figure 4.4). showing increased relative hazard at both low and
tugh SBP. Although this observation could be an artifact, the strength of the association
argues in favor of a real effect. Moreover, both extremes of blood pressure have been
linked with adverse cardiac evenlS in other patient populations, notably dialysis [46}.
Since high blood pressure is known to promole endothelial dysfunction, atherosclerosis,
and LVH. a causal relationship between hypertension and de novo lHD is likely. At the
other extreme, lhe association between low blood pressure and adVCTSC prognosis may be
non-causal. Low 8P is thought 10 be a marker of the severilY of underlying cardiac
dysfunction. which in tum detennines survival. Because the cohort studied was selected
on the basis of being clinically free of heart disease, it is unlikely, bUI possible, lhat the
presence ofoccult cardiac disease is responsible for the observed J-curve. Alternatively, a
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causal relarionship may exist if low SP is a result of excessive or inappropriate trcalment
with antihypertensive agents. leading 10 coronary hypoperfusion and DID. In this regard,
Kasiske ct al ltave observed an association between dihydrop)Tidine use and de novo
DID in RTR [7]. Other studies in the general population have suggested a similar
association for short acting dihydropyridines [136.137] . We are unable to show a
significant association between type or number of antihypertensives and either low blood
pressure or DID in the present data set, however.
Some authors have suggested that SSP may be a marker for pulse pressure (PP ., OBP·
SBP) [24.138]. Elevated pulse pressure is thought to reflect increased total arterial
impedance., an index of diffuse arterial stiffening (arteriosclerosis). which has been linked
to cardiac disease independently of mean arterial blood pressure [139J. We explicitly
tested for this possibility by incorporating PP into the model. either alone or in
combination with OBP or mean arterial pressure (MAP=(2·0BP+SBP)'J). PP could not
be successfully incorporated, however. suggesting that increased SSP is more than an
indirect marker of elevated arterial impedance and target organ damage. These
observations funller support a causal link between elevated SBP and lHD.
Our results overall suppon the hypothesis that Mood pressure is a causal risk. factor for de
novo CHF. DID and monality in renaJ. transplant patients.. Clinical trials in this
population are needed 10 definitively establish causality and 10 determine appropriate
treatment targets.
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AMit»IuII rUkjlldMs ftw til ...180
Cholesterol: High tota! cholesterol has been shown to be an independent predictor of
cardiovascular events and mortality in the general population (96]. In dialysis patients.
low cholesterol is a predictor of mortality. most likely because it is a marter of
malnutrition [100]. High cholesterol has been associated with cardiovascular
complications in transplant patients [6].
In the present study. high cholesterol was independently associated with cardiovascular
death, whereas low cholesterol was associaled with non<ardiovascuJar death. This
finding is consistent with the hypothesis that hypercholesterolemia is causally related to
the development of urn in the tr.Insplant population. Conversely. low cholesterol may be
a marker of general comorbidity or malnutrition, which in tum may be associated with
non-cardiovascular death. lbese results therefore. are biologically plausible. Since
cardiovascular and non<ardiovascular deaths were equal in nwnbcr in this cohort, and
since the impact of cholesterol on each was opposite and of approximately equal
magnitude. these effects would be expected to cancel each other out in the analysis of all
cause death, as was observed.
Several important limitations to this interpretation deserve mention. First, the analysis of
cause specific death is confounded by the problem of competing outcomes: if II. patient is
observed to die from cause A. that patient cannot also be observed to die from cause B. It
is possible to argue, for example. that low cholesterol is causally associated with non-
cardiovascular death. Patients dying of non-cardiovascular causcs cannot be observed to
die of cardiovascular causcs. 1l1osc patients dying of cardiovascular causes will tend to
80
have higher cholcstero~ leading to spurious., DOI1<ausal association between high totaJ
cholesterol and CV death. (The reverse argument can be made as well: a causal
association between hypm::holesterolemia and CV death and a spurious association
between non-CV death and low cholesterol). On the basis of biological plausibility.
however. we favor a real and causal association between hypercholesterolemia and
cardiovascular mortality, and a real but non-causal association between low cholesterol
and non-cardiovascular death.
The second limitation is that only two thirds of the patients studied had total cholesterol
levels done in the fim year, compared 10 90-100% for most other paramelcrs. Not
surprisingly, cholesterol was found to be the parameter most sensitive 10 random
imputation. 1luec of the five randomly imputed data sets gave models similar to the one
discussed. whereas two ofthe five excluded cholesterol. However, restricting the analysis
to those patients in whom cholesterol was measured. or using a multivariate normal
imputation method, both led to paramcler estimates for cholesterol very similar to those
in the analysis presenled here.
Finally, we did no! show an independent contribution of high cholcstcrolto lHD events
as one woukl expect. However, cholesterol was included in a multivariate model when
blood pressure was excluded. Introduction of blood pressure tenns rendered the
cholesterol tcnn non-significant and markedly diminished the hazard ratio associated
with hypercholesterolemia. This model behaviour indicates the presence of confounding
bias betWeen blood pressure and cholesterol. The observation of confounding bias
between b'aditional risk factors is not surprising; indeed, the term "Canbovascular
Dysmctabolic Syndrome (CDS)" has bcc:n used to describe the clustering of
8\
hypertension, hypcrliptdmUa. obesity. and insulin resistance/diabetes {140]. Our event
rate was likely 100 small to simultaneously resolve the independent contribution of both
blood pressure and cholesterol.
We conclude thai: hypercholesterolemia is probably a risk fac:lOr for mo, although the
evidence is less robust and convincing than for the other risk factors.
Anemia: Anemia has been associated with l VH and l V growth in chronic renal failure
patients not on dialysis, and with LVH. LV dilatation, and clinical CHF in dialysis
patients (23.50). Cornction ofthc anemia may prevent LV dilatation in dialysis patients
with normal hearts at baseline [141]. In the present study. anemia was found to be an
independent risk factor for de novo CHF. all-cause and non-CV monality. Even relatively
mild anemia (hgb<120) was associated with increased risk of CHF and all-cause
monaJity. Since the need for increased cardiac: outpUt may plausibly lead to eccentric
LVH and ultimately diastolic or systolic dysfunction. the association between anemia and
de novo CHF is probably causal. Alternatively. it is possible that anemia simply unmasks
occult ventricular dysfunction. Although the cohon was free of clinical CHF at baseline
and during the first year, cchocardiography was not done and so occult LV dysfunction
cannot be completely excluded. Moreover, anemia was correlated with renal impairment,
and so could be a surrogate marker for a failing allograft, fluid overload. and consequent
CHF. However, low hemoglobin consistently displaced creatinine clearance in the
multivariate models of de novo CHF. suggesting an independent effect. On balance. our
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data support but do not prove a causal role for anemia in the development of de novo
CHF in RTR.
The role of anemia as a predictor of mortality is more difficult to interpret. Anemia
predicted all-aU5e and non-CV mortality but not CV mortality, suggesting a non-CV
mechanism. In this instance. anemia could be a marker for systemic disease such as
neoplasia, infection, progressive allograft failure, autoinunune disease. or marrow
suppression. A more discerning analysis of the determinants of anemia in this transplant
cohon is planned and may shed light on this issue. Ultimately, however, the question of
whether anemia is a causal risk factor amenable 10 intervention can only be answered by
a c1inicaluial of anemia correction in transplant patients with chronic anemia.
Renal insufficiency per se has been associated with adverse risk of death in several cross·
sectional surveys. This effect has been found 10 be statisticaJly independent of age,
gender, hypertension and CAD. Such observations have suggested that uremia per se.,
independent of effects on hypenension, anemia, lipids and so forth. may exert an
accelerative affect on cardiac disease. Prevalence studies, however, cannot discern
whether renal insufficiency is a cause of CVD or a marker for other causal factors. In the
prospective Framingham Hean Study cohan, the CVD event rate in men with mikl R1
was 21.3/1000 person years and 25.6 in women vs. 18.5 in men and 11.0 in women with
nonnal serum creatinine. However, R1 was not an independent risk factor for CVD in
men or women, after adjustment for age, body mass index, diabetes. systoltc blood
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pressure. antihypertensive agents. total cholesterol, HDL cholesterol, smoking, prevalent
CVD, use of cardiac medications, and left venlricular hypertrophy [142}.
in the present study. we did not find renal function, as estimated by the Gault-Cockroft
creatinine clearance (CCr), to be an independent predictor ofCHF or nID. With respect
to de novo CHF, CCr was replaced by anemia in the multivariate model, suggesting that
its univariate impact was mediated primarily by anemia and blood pressure. CCr was not
a significant predictor ofde novo nID in either the univariate or multivariate models.
In the present study, it would seem that the impact of renal insufficiency on cardia<:
disease is I) apparent only with respect to disorders of cardiac function (CHF) and not
perfusion (ffiD) and 2) is largely accounted for by blood pressure and anemia. known
correlates of renal failure.
Donor type, acute rejections in the first year, and delayed graft func:tion have all been
associated wilh poorer graft and patient survival [4,6,9]. In addition, it has been
suggested that cyclosporine is a risk factor for cardiovasc::ular disease [21,60}. However,
with the exception of anemia, which is discussed separalely, transplant-related risk
factors were not s[rOngly assoc:iated with outcome in the present study. Only DGF in the
case of de novo CHF and acute rejection in the case of de novo lHD were significant in
the multivariate models. This occurred despite the fact that we analyzed de novo events
in patients free of cardiac disease in their first transplant year, a strategy designed to
enhance the sensitivity to transplant related variables.
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The link between transplant variables and cardiovascular risk found in previous studies
may reflect direct or indirect causality, or result nom a non~usal association. For
example., DGF and rejections may be associated with a systemic inflammatory response,
endothelial activation. and canliovascular disease (67]. Cydosporinc is an endothelial
toxin. enhances platelet activation, enhances oxtdation of LDL and may thus also directly
promote atherosclerosis (64-66). On the other hand, the laner variables are associated
with graft failure and hypertension, while cyclosporine is linked to hypertension and
hypercholesterolemia (22.60]. Under this latter scheme. an indirect link between
transplant associated variables and outcome would be mediated via "traditiona.l" risk
factors such as blood pressure and high cholesterol. Our study results arc more consistent
with the latter hypothesis. since the impact of transplant-associated variables is weaker
than age, diabetes. blood pressure and cholesterol when the effect of these variables is
adequately taken into account. Our results support the hypothesis that traditional
cardiovascular risk factors plus anemia arc the major causal detcnninants of
canliovascular outcomes in transplant patients.
U",lttltitHtso!tltetllftdysis
The cohan design used is consKlercd more reliable than casc-control or cross-sectional
designs. The major disadvantages of rctrolective vs. prolective cohort designs are that in
the former. data may at times be missing. the assessment of risk factors and outcomes
may be subjcct to bias because they may not have been defined a priori as is the case with
a prolective design, and cenain risk factors and outcomes of interest may not have been
assessed in the past. In the case of the present database, two of these methodological
pitfalls are minimized. The exclusive fonaw-up of patients by a single renal transplant
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program operating in relative geographic isolation in a province with a stable population
has pcnniucd excellent data capture over a long follow-up period (up to 29 years). Most
of the risk factors of interest were obtained as part of the clinic protocol. The availability
of complete outpatient and hospital records has allowed the application of a priori study
definitions to outcome events. The reliability of the data may thus approach that of a
prospective cohort study.
With respect to the third limitation. there arc scven.l risk factors that we could not
analyze. lipoprotein fractions (LDL, HOL) were available in only half the patients in
whom cholesterol was measured. Lp(a) and homocysteine were not routinely measured
until recently. Cytomegalovirus (CMV), which has been associated with endothelial
dysfunction, was measured at baseline in patients only after 1990. representing less than
50"1. of the present cohort. Prospective cohort studies will be neccssaJY to analyze these
factOfS.
Finally. the present study looked at detenninants of de novo cardiac events after the first
year. This was done in order to lessen the confounding impact of pre-existing rena]
disease in this population. Since we did not analyze outcome events occurring in the early
post-transplant period. we cannot comment on risk factors for CVD in the first year after
transplantation. Many of these risk factOfS will pertain to exposures during chronic renal
insufficiency and dialysis, and may well be different from those identified in this study.
4.5 CoaduskJas
Dc novo CHF occurs as conunonly as de novo mo. and appears to carry a similar
adverse prognosis. The incidence of CHF was considerably higher than observed in the
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Framingham cohort. whereas the incidence of IHD was remarbbly low, of the same
order as observed in the Framingham study cohort. Age, diabetes, gender, blood pressure
and anemia, appear 10 be the dominanc factors in !he development of de novo CHF, while
age, diabetes, gender, blood pressure and cholesterol appear to be the dominant risk:
faclors for de novo am in renal transplant recipients. Once lhese strong risk factors are
taken into accounl, the incremental impacl of renal function, delayed graft function and
graft rejection on all outcomes is small, and cytlosporine use does not appear 10 be a rislc
factor at all. Optimal strategies for treatmenl of blood pressure, anemia and cholCSlerol
will need 10 be delennined by randomized clinical trials.
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CHAPTERS:
GLOBAL SUMMARY: ARE THE PARADIGMS OF CARDIAC DISEASE STILL
VALID?
88
S.l 1'IIncIipB ofeanli. disease • RTR
Historically, cardiac complications in patients with renal disease have been thought
parenthetic to the process of uremia. From the 1970's onwards, the observation of an
elevated prevalence of both LV functional disorders and lHD in dialysis led to concepts
of"accelen.ted atherosclerosis" and ""uremic cardiomyopathy'". These tenns renec:ted the
belief that the rate of development cardiac disease was accelen.tcd by loss of renal
function and that uremia intrinsically modified these processes independently of known
risk factors. These arguments were supported by registry data and prevalence studies
showing an excess burden of cardiovascular mortality after adjustment for known risk
factors [143,144] . More recent studies of incident events in prospective cohorts have
questioned this view. Renal dysfunction may not be an independent predictor of incident
DiD. once traditional risk factors have been taken into account. and the association of
renal failure with LV disorden may be largely explained by the excess prevalence of
hypertension and anemia (69.142].
Although the prevalence of cardiac disease is much lower in RTR. the paradigm of
"accelerated atherosclerosis" has been extended to this population [JI. Emphasis has been
placed on the immunological milieu. in accordance with the traditional view of renal
transplantation as an immunological disorder. In contrasl, the notion of a transplant
specific "cardiomyopathy" has not developed, in large part because relatively few studies
have looked at the question of LV functional disorders in the renal transplant setting.
Since our own data appear to contradict the prevailing view of cardiac disease in uremia,
it seems appropriate to revisit these concepts as they pertain to RTR.
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In ESRD patients, the notion of a toxic "uremic cardiomyopathy" derives from the
experience, now rare, of a severely uremic patient with a dilated. poorly contractile hean
that becomes normally functional after institution of dialysis. Patients with persistently
poor systolic function (fractional shortening <25%) prior to renal transplantation seem to
show normalization of systolic function after transplantation (36]. These observations
have suggested the presence of an unmeasured uremic factor (or combination of factors),
which is removed upon partial or complete restoration of renal function (dialysis or renal
transplantation).
In conlrast to the indirect evidence cited above, a careful analysis of a prospectively
followed CRI cohort showed that the impact of declining renal function on progression of
LVH was largely accounted for by anemia and hypertension [23J; that is, the LVH ofCRI
seemed to be the consequence not of retained uremic toxins, but of chronic flow (anemia)
and pressure (hypertension) overload. Our own data in RTR arc strikingly similar. In the
present analysis, age and blood pressure were the key determinants of persistent cardiac
hypenrophy during transplantation, while age, gender, diabetes, blood pressure, and
anemia, were the key predictors of de novo CHF. The fate of the heart in RTR appears
dominaled by the same hemodynamk: factors operative in CRI.
The similarity between RTR and CRt patients is worth exploring further. Halloran et aI.,
among others, have documented Ihe importance of non-immune mechanisms such as age,
nephron dosing, and blood pressun:, in the progressive loss ofgnft function. These non-
immune factors appear 10 dominate after the first post-transplant year [145J. They have
90
promoted a new terminology, chronic allograft nephropathy (CAN) as opposed to
"chronic rejection", in Ofderto more accur.uely describe a process ofrena.l attrition !hal is
onJy partly immune mediated [146]. In this light, CAN is analogous to loss of renaJ
function in native kidneys with chronic autoimmune nephropathies, in which both
immune activity and non-immune factors (particularly blood pressure) conlributc to renal
decline. The National Kidney Foundation Task Force on Cardiovascular Disease seems to
sanction this view and considers RTR a special case ofCRI (147).
Our own data are congruent with Ihe wider literature on the pre-eminence of non-immune
factors in graft and patient outcomes in renal transplantation. LV functional disorders in
RTR appear to result primarily from pressure and flow overload (anemia), observations
analogous to those in CRI. We find little evidence ofa "'toxic", "uremic" or "transplant"
cardiomyopathy. The implication of such a shift in paradigm is that greater emphasis
could be placed on potentially treatable complications of renal transplantation such as
hypertension and anemia.
5.3 Accderllted atllerosdentsis
The term "accelerated atherosclerosis" implies a higher rate of development (i.e. a higher
incidence) of nm in RTR. A direct comparison of incident IHD in RTR and the GP,
controlling for differences in risk·factor profile, has not been done, however. The
incidence is generally assumed to be higher, based on Ihe known higher pt'f!W1lence of
lliO in RTR compared with the general population. This inference is not necessarily
valid and requires objective confirmation in prospective studies directly measuring the
incidence ofnew DID in both the RTR and GP.
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We observed a rate of de novo am of 1.25% pel" year in the present cohort. It is
imeresling 10 note thallhe crude incidence ofCVO in the Framingham sludy was 1.8'1.
per year for males and 1.1% per year for females [142J. These rates arc: 001 strictly
companble because the endpoints differ. recurrent disease was included in the
Fnuningham study, and adjustment for differences in population characleristics such as
diabetes, age, gender and hypertension have not been made. Nevertheless the event rates
for de novo nm in RTR and the GP may be similar, rather than several-fold higher as
currently believed. We observed further thaJ. the dominant factors for de novo am were
concordanl with the traditional, Framingham type risk factors: age. diabetes, and blood
pressure. The contribulion of lransplant variables was less important. The portrait of lHD
in RTR that emerges from our study is one that is broadly similar in frequency and risk
factor profile to that in the genera.l population. This is not to say transplant and rena1
failure related variables arc: irrelevant; rather. the contribUlion of these variables is
probably exerted indirectly, mediated via changes to traditional rislc factors such as
diabetes and blood pressure. What residual direct influence they exert on the
atherosclerotic process is likely of a minor and modulatory nature. As was the case with
LV functional disorders. our analysis shifts emphasis away from the immunological
paradigm. Our work supports the idea that the development of lHD in RTR is
fundamentally similar to that in the GP, while the evolution of clinical disorders of LV
function and geometry is similar to that in CRI.
We have suggested in this paper that existing paradigms of heart disease in renal failure,
based as they are on analyses of prevalent disease or of incident disease in populations
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with a high baseline prevaknce of heart disease, may be inaccurate. From a
methodological viewpoint. it is imperative that incident CVD in renal populations with a
(ow baseline prevalence of heart disease (i.e. CRJ and RTR cohorts) be intensively
studied, since only in such populations can one adequately eliminate the confounding by
reverse causality inherent in populations with a high baseline prevalence of heart disease.
Examination of comorbidity-adjustcd incident event rates for CHF and nm in GP. CRJ.
and RTR cohorts, using similar definitions and statistical procedures. are n~ed to more
rigorously compare these palient populations., and to help shed light on differences in
causation. if any exist. Such analyses are being planned. Our observations further suggest
that patients may benefit from more aggressive treatment of reversible risk factors such
as hypenension, anemia, and hypercholesterolemia than is currently practiced. Clinical
trials will be necessary to confirm the value of aggressive interventions on these risk
factors and to determine optimal treatment thresholds.
The importance of anemia as a risk factor fOf LV dysfunction in RTR is a new
observation, and menU further exploration. A causal relationship between anemia and
CHF would be further supported by evidence that the impact of anemia on CHF is
mediated by the development of LVH. Such an analysis. using EKG criteria for LVH.
will be perfonned on this cohort in the near future. Ultimately. intervention trials of
aggressive anemia management in RTR must be done in order to Vlllidate the causal
inferences drawn from observational studies.
The risk factors for cardiac disease in any population have not been completely defined.
Even in the GP, risk models predict only haIf of all events. In RTR,
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hyperbomocystcinemia and CMV infections are potential but unproven causal agents for
IHD. Further insights will undoubtedly accrue on these risk faclon.
The notion that genetic variation may explain much of the ~idual rislc for cardiac
disease in many populations is a new and promising one. Nascent gene chip technology
may facilitate explocation of the cardiac impact of genes coding for peptidcs and proteins
involved in vascular/endothelial regulation. apoptosis. acute and chronic inflammation,
mutagenesis, and repair. Our immunology laboratory in WiMipeg, under the direction of
Dr. Peter Nickerson, is presently able to identify allelic variation in the genes coding for
six cytokines involved in inflammation and repair (1L-IO. TNf.·a. IL-6. TGF-(3. lFN-y).
We have begun to enroll an inception cohan of dialysis patients in order to explore the
impact of allelic variations in these genes on cardiovascular outcomes in dialysis. As
discussed at the beginning of this sec::tion, this study must expand to CRJ and RTR
cohons in order to reduce survivonhip bias and confounding by revene causality. We
hope this novel direction of inquiry may help explain the remaining SO% of
cardiovascular events that cwrent models cannot predict
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